LONDON (ShareCast) - AIM-listed Pharmaceuticals group Scancell Holdings announced a patent for its DNA ImmunoBody technology has been approved in the US.

The patent has been granted by the United States Patent and Trademark Office (USPTO) and covers Scancell's DNA ImmunoBody platform technology.

This patent is expected to be “key” for the protection of the company's pipeline of ImmunoBody vaccines and follows the grant of counterparts in Australia, China and Japan.

Joint Chief Executive Richard Goodfellow said: "We are delighted to have further strengthened our IP portfolio around our proprietary ImmunoBody platform technology.

“The United States is a key market for us and this, alongside the recent positive results from the Phase 1/2 trial for our SCIB1 ImmunoBody in melanoma, demonstrates the strong progress Scancell is making."

The group said on Monday its shares advanced after announcing “encouraging results” from the clinical trial of its SCIB1 ImmunoBody drug for the treatment of stage III/IV melanoma.

As of 09:31 the share price had risen 3.88% to 32p.

WS

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE